6. Within 7 days before screening (including 7 days), laboratory test data requirements were as follows: neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥90g/L (no blood transfusion within 14 days), serum total bilirubin ≤1.25 times the upper normal limit (ULN);ALT and AST≤ 2.5 x ULN (≤5x ULN in patients with liver metastasis);Serum creatinine ≤1.0 x ULN and creatinine clearance rate ≥60 mL /min;Left ventricular ejection fraction in ultrasound examination \>55%;
7. At least one measurable lesion (RECIST 1.1 criteria);
8. Subjects (or their legal representative/guardian) must sign the informed consent indicating that they understand the purpose of the study, understand the necessary procedures of the study, and are willing to participate in the study.
You may not be if
Those who have one or more of the following will not be included in the study:
1. Have received any experimental drugs or anti-tumor drugs within 4 weeks before enrollment;
2. A history of other tumors in the past five years, except for cervix cancer or basal cell carcinoma of the skin that has been cured;
3. Patients with obvious intracranial hypertension or neuropsychiatric symptoms due to uncontrolled primary brain tumor or central nerve metastatic tumor
4. Pregnant or lactating women;Those who are fertile but do not take adequate contraceptive measures;
5. Alcoholism or drug addiction;
6. with pleural effusion or ascites, causing respiratory syndrome (≥CTCAE2 grade dyspnea), requiring local treatment;
7. Patients with the following serious or uncontrolled diseases: severe heart disease, unstable condition after treatment, myocardial infarction, congestive heart failure, unstable angina pectoris, pericardial effusion with obvious symptoms or unstable arrhythmia within 6 months before enrollment;Definite neuropathy or psychosis, including dementia or seizures;Severe or uncontrolled infections;Patients with active and disseminated intravascular coagulation and significant bleeding tendency
8. known hypersensitivity or anaphylaxis to any component of the study drug to be applied.
9. The function of important organs is obviously impaired
10. Other circumstances under which the investigator considers that the patient should not participate in the study
Clareo Health | Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
